'Y­ou are not the drug spon­sor': FDA de­clines pe­ti­tion to anoint Cas­sava's drug as 'break­through'

A cit­i­zen asked the FDA last Oc­to­ber to im­me­di­ate­ly give Cas­sa­va Sci­ences’ Alzheimer’s drug can­di­date simu­fil­am the cov­et­ed break­through ther­a­py tag, which short­ens the time­frame …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER